Access Advocate for Clinical Research Participation
Supports US and Canadian clinical sites to implement and evaluate Access Advocate roles that increase inclusive participation in Parkinson’s disease research trials.
Funder: Michael J. Fox Foundation for Parkinson's Research
Due Dates: May 11, 2026 (Q&A Session) | May 15, 2026 (Q&A Session)
Funding Amounts: Funding supports Access Advocate implementation at clinical sites; specific award size and duration not stated—refer to program overview.
Summary: Supports clinical sites in the US and Canada to implement Access Advocate roles that increase inclusive and representative participation in Parkinson’s disease research.
Key Information: Only sites with active or planned interventional PD clinical trials in the US or Canada are eligible.
Description
This program aims to increase inclusive participation in Parkinson’s disease (PD) research by funding clinical sites to implement and evaluate the Access Advocate model. Access Advocates are tasked with developing practical, relationship-based pathways to enhance representative enrollment and retention in clinical studies. The initiative emphasizes well-defined advocate roles, repeatable participant identification and support workflows, and systematic tracking of recruitment, retention, and health system outcomes. Cross-site collaboration is encouraged to refine the model and share effective practices.
